The Role Of Purines In Age Related Macular Degeneration
Funder
National Health and Medical Research Council
Funding Amount
$682,434.00
Summary
Age Related Macular degeneration (AMD) is a leading cause of blindess. In this project we will examine a possible cause for the development and progression of early AMD. In particular we will determine whether signaling of immune cells via receptors called purinergic receptors influences the removal of cellular debris as we age, predisposing people to the disease.
Novel Photoreceptor Bioenergetics: Basic Science And Clinical Translation
Funder
National Health and Medical Research Council
Funding Amount
$701,088.00
Summary
In this project we will investigate how the light-sensitive cells in the eye (the photoreceptors) use energy and make special pigments that convert light to electrical signals. We will test novel treatments that enhance the energy supply of the photoreceptors in individuals with age-related macular degeneration.
Do Activated Retinal Microglia Mediate Neurotoxicity In Background Diabetic Retinopathy?
Funder
National Health and Medical Research Council
Funding Amount
$435,589.00
Summary
Diabetic retinopathy, a frequent complication of Type 1 and Type 2 diabetes, is the commonest cause of blindness in working age individuals. Prior to the growth of blindness-causing new vessels in the eye we now know that there is a gradual loss of neurons in the retina. This project will investigate whether the resident immune cells in the retina, which are normally neuroprotective, become neurotoxic during episodes of systemic inflammation (e.g. bacterial or viral infections).
Nanoparticle-based Anti-VEGF Treatment For Ocular Neovascularization
Funder
National Health and Medical Research Council
Funding Amount
$576,921.00
Summary
Diseases like AMD and DR are the leading cause for substantial and irreversible vision loss as a direct effect of pathologic ocular neovascularization and have a significant economic impact on individuals, families, health systems and countries. Nowadays, the treatment requires frequent intravitreal injections of anti-VEGF antibody with all the risks of an invasive intraocular procedure. Nanotechonoly-based drug delivery system will provide a less invasive treatment for this kind of disease.